scholarly journals Do pregnancy outcomes differ by mode of insulin delivery for type 1 diabetes mellitus?

2022 ◽  
Vol 226 (1) ◽  
pp. S47
Author(s):  
Nasim C. Sobhani ◽  
Akshaya Kannan ◽  
Nicole K. Tantoco ◽  
Sophie Patzek
2019 ◽  
Vol 24 (2) ◽  
pp. 99-106
Author(s):  
Michelle Condren ◽  
Samie Sabet ◽  
Laura J. Chalmers ◽  
Taylor Saley ◽  
Jenna Hopwood

Type 1 diabetes mellitus has witnessed significant progress in its management over the past several decades. This review highlights technologic advancements in type 1 diabetes management. Continuous glucose monitoring systems are now available at various functionality and cost levels, addressing diverse patient needs, including a recently US Food and Drug Administration (FDA)–approved implantable continuous glucose monitoring system (CGMS). Another dimension to these state-of-the-art technologies is CGMS and insulin pump integration. These integrations have allowed for CGMS-based adjustments to basal insulin delivery rates and suspension of insulin delivery when a low blood glucose event is predicted. This review also includes a brief discussion of upcoming technologies such as patch-based CGMS and insulin-glucagon dual-hormonal delivery.


2011 ◽  
Vol 2 (2) ◽  
pp. 86-93 ◽  
Author(s):  
Kazuki Tajima ◽  
So Nagai ◽  
Hideaki Miyoshi ◽  
Takuma Kondo ◽  
Shigeki Shimada ◽  
...  

2018 ◽  
Vol 12 (3) ◽  
pp. 136-142
Author(s):  
Benjamin RS Dixon ◽  
Alison Nankervis ◽  
Stephanie CN Hopkins ◽  
Thomas J Cade

Background Insulin delivery options for pregnant women with type 1 diabetes mellitus are either continuous subcutaneous insulin infusion or multiple daily injections. The aim of this paper is to compare pregnancy outcomes in women with type 1 diabetes mellitus using continuous subcutaneous insulin infusion or multiple daily injections in pregnancy. Methods Retrospective single-centre cohort study of 298 pregnancies booked between 2006 and 2016. Descriptive analysis was performed for HbA1c values. Logistic regression models were created to compare selected maternal and neonatal outcomes. Results Continuous subcutaneous insulin infusion was associated with increased risk of large-for-gestational age (aOR 2.00, 95% CI 1.20–3.34) and preterm neonates (aOR 1.80, 95% CI 1.04–3.03). Continuous subcutaneous insulin infusion had no association with increased risk of adverse pregnancy outcomes. No difference in HbA1c values existed between groups. Conclusion Using continuous subcutaneous insulin infusion for type 1 diabetes mellitus through pregnancy is associated with increased risk of large-for-gestational age and preterm neonates, without increased risk of associated adverse maternal or neonatal outcomes.


Sign in / Sign up

Export Citation Format

Share Document